Key Indicators of Value and Success in a Life Sciences Company

04 December 2007 Past Event

In any due diligence process, knowing the assumptions that drive the value estimate and the methodology used to balance anticipated investments, risks, and rewards will allow for a company to adjust the diligence review accordingly. This discussion will cover:

  • Approaches for developing valuation and valuation assumptions for in-licensing, M&A, IPO, and R&D
  • Evaluating the future impact of key items when reviewing a biotech IP portfolio
  • Identifying factors that executives use to arrive at a starting value, and then quantifying the deductions depending on the results of the IP due diligence
  • Valuation methodologies used for early-stage vs. late-stage products

Panelists include: Gregg Alton, Senior Vice President and General Counsel, Gilead Sciences, Inc.; Doug Crawford, Associate Executive Director, QB3; Doug Sheehy, Vice President & General Counsel, Codexis, Inc.; and Paul Stewart, Partner, Foley.

Insights

Telehealth: Medicare Finalizes New Services for 2020 in Physician Fee Schedule
11 November 2019
Health Care Law Today
Longstanding EB-5 Visa Program Undergoes Significant Changes
11 November 2019
Labor & Employment Law Perspectives
State Data Breach Notification Laws
11 November 2019
DOJ Announces Procurement Collusion Strike Force
08 November 2019
Legal News: Government Enforcement Defense & Investigations
PATH Summit 2019
18-20 December 2019
Arlington, VA
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
Fall NAIC Meeting Reception
07 December 2019
Austin, TX